REGISTERED NUMBER: 10871140 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31 December 2024

for

Bodybio Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

B Berman

SECRETARY:

B Berman

REGISTERED OFFICE:

1010 Cambourne Road

Suite 305

Cambourne

Cambridge

Cambridgeshire

CB23 6DP

REGISTERED NUMBER:

10871140 (England and Wales)

ACCOUNTANTS:

Knights Lowe Chartered Accountants

Eldo House

Kempson Way

Suffolk Business Park

Bury St Edmunds

Suffolk

IP32 7AR

FIXED ASSETS

Intangible assets

4

5,012

6,237

CURRENT ASSETS

Stocks

140,147

158,546

Debtors

5

89,026

108,252

Cash at bank

62,131

12,474

291,304

279,272

CREDITORS

Amounts falling due within one year

6

192,172

329,306

NET CURRENT ASSETS/(LIABILITIES)

99,132

(50,034

)

TOTAL ASSETS LESS CURRENT LIABILITIES

104,144

(43,797

)

CREDITORS

Amounts falling due after more than one year

7

669,679

452,961

NET LIABILITIES

(565,535

)

(496,758

)

CAPITAL AND RESERVES

Called up share capital

8

1

1

Retained earnings

(565,536

)

(496,759

)

SHAREHOLDERS' FUNDS

(565,535

)

(496,758

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 16 December 2025 and were signed by:

B Berman - Director

1.	STATUTORY INFORMATION

Bodybio Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised on accruals basis when goods are dispatched to customers.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, and loans from banks or other related parties.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern

The financial statements have been prepared on the going concern basis which assumes that the company will continue in operational existence for the foreseeable future. Having assessed the projected results and cash flow of the company, it is expected that the company will start trading and produce profits and generate cash in the year ended 31 December 2025. The company retains the support of the company's parent company via an inter company loan and funding when required. It is expected this arrangement will continue for the foreseeable future. Whilst there is always considerable uncertainty in predicting cash flows more than a few months into the future, the directors are confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis.

Impairment

At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in the income statement.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4.	INTANGIBLE FIXED ASSETS

Patents

and

licences

£

COST

At 1 January 2024

and 31 December 2024

12,251

AMORTISATION

At 1 January 2024

6,014

Amortisation for year

1,225

At 31 December 2024

7,239

NET BOOK VALUE

At 31 December 2024

5,012

At 31 December 2023

6,237

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade debtors

79,771

65,791

Other debtors

9,255

42,461

89,026

108,252

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade creditors

85,236

254,486

Taxation and social security

65,636

41,236

Other creditors

41,300

33,584

192,172

329,306

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2024

2023

£

£

Other creditors

669,679

452,961

Other creditors due after more than one year is made up of amounts owed to group companies.

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

2024

2023

value:

£

£

1

Ordinary £1

£1

1

1

9.	ULTIMATE CONTROLLING PARTY

The company's parent company is Bodybio Inc. A company registered in USA at 45 Reese Road , Millville, New Jersey 08332